Suzuki Takashi, Shimada Hideaki, Nanami Tatsuki, Oshima Yoko, Yajima Satoshi, Washizawa Naohiro, Kaneko Hironori
Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Int J Clin Oncol. 2017 Jun;22(3):461-468. doi: 10.1007/s10147-016-1087-5. Epub 2017 Jan 7.
Preoperative hyperfibrinogenemia is associated with inflammatory mediators and a poor prognosis in several types of cancer. However, there is no published information on the monitoring of patients with preoperative hyperfibrinogenemia after surgery. The aim of the study reported here was to assess the clinicopathological and prognostic significance of plasma fibrinogen levels in patients with esophageal squamous cell carcinoma before and after surgical treatment.
Plasma fibrinogen levels were analyzed before surgical treatment (endoscopic submucosal dissection and surgery) in 82 patients with esophageal squamous cell carcinoma. The clinicopathological significance of plasma fibrinogen levels and the relationship of plasma fibrinogen levels with several biomarkers were evaluated. The cutoff value for hyperfibrinogenemia was 321 mg/dl. Univariate and multivariate analysis using the Cox proportional hazards model were performed to evaluate the prognostic significance of plasma fibrinogen levels. The changing patterns of plasma fibrinogen were monitored after surgical treatment to evaluate prognostic impact.
Hyperfibrinogenemia was significantly associated with advanced pathological stage of cancer and high C-reactive protein levels. Plasma fibrinogen levels significantly decreased after surgical treatment in recurrence-free patients but did not decrease in patients with recurrence. The multivariate analysis indicated that preoperative hyperfibrinogenemia was an independent prognostic factor for poor survival (hazard ratio 1.005, 95% confidence interval 1.000-1.010; P = 0.039).
Preoperative hyperfibrinogenemia was associated with inflammatory mediators, tumor progression, and poor survival in patients with esophageal squamous cell carcinoma. The absence of a decrease in plasma fibrinogen levels after surgical treatment may indicate the possibility of tumor recurrence.
术前高纤维蛋白原血症与多种癌症中的炎症介质及不良预后相关。然而,关于术后监测术前高纤维蛋白原血症患者的信息尚未见报道。本文所报告研究的目的是评估食管鳞状细胞癌患者手术治疗前后血浆纤维蛋白原水平的临床病理及预后意义。
对82例食管鳞状细胞癌患者在手术治疗(内镜黏膜下剥离术和手术)前分析血浆纤维蛋白原水平。评估血浆纤维蛋白原水平的临床病理意义以及血浆纤维蛋白原水平与几种生物标志物的关系。高纤维蛋白原血症的临界值为321mg/dl。使用Cox比例风险模型进行单因素和多因素分析,以评估血浆纤维蛋白原水平的预后意义。监测手术治疗后血浆纤维蛋白原的变化模式以评估预后影响。
高纤维蛋白原血症与癌症的晚期病理分期及高C反应蛋白水平显著相关。无复发患者手术治疗后血浆纤维蛋白原水平显著降低,但复发患者未降低。多因素分析表明,术前高纤维蛋白原血症是生存不良的独立预后因素(风险比1.005,95%置信区间1.000 - 1.010;P = 0.039)。
术前高纤维蛋白原血症与食管鳞状细胞癌患者的炎症介质、肿瘤进展及不良生存相关。手术治疗后血浆纤维蛋白原水平未降低可能提示肿瘤复发的可能性。